Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β‐Cell Regeneration, Immune Modulation, and Exosome‐Mediated Glucose Homeostasis
Stem Cells International · 2026-01 · 2026 (1)
DOI: 10.1155/sci/2759804 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stem Cells International, online erschienen am 13.06.2026. Verfasst von Jia Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu…. Die Arbeit nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance, and a progressive decline in pancreatic β‐cell function, leading to impaired glucose regulation. It is often accompanied by severe complications, including cardiovascular diseases, nephropathy, and retinopathy. Conventional treatments, such as sulfonylurea pills, insulin injections, and GLP‐1 receptor agonist injections, provide transient glycemic control but are often costly with unstable efficacy and long‐term side effects. Pancreatic islet transplantation, while effective in some cases, is limited by donor scarcity, graft rejection, and the need for lifelong immunosuppression. Recently, mesenchymal stem cells (MSCs) have emerged as a promising alternative due to their multipotent differentiation potential, immunomodulatory properties, and regenerative capabilities. This review examines the therapeutic roles of MSCs in β‐cell regeneration, inflammation modulation, and tissue repair while also addressing key challenges in clinical translation. However, given the lack of long‐term clinical data, the conclusions presented remain preliminary and should be interpreted with caution. This article, therefore, aims to provide a foundational reference for future research, rather than definitive clinical guidance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Plastic Surgery and Burn Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, 515051, Guangdong, China, stu.edu.cn.
- Guangdong Provincial Key Laboratory of Marine Biotechnology, Department of Biology, College of Science, Shantou University, Shantou, 515063, Guangdong, China, stu.edu.cn.
- Plastic Surgery Institute of Shantou University Medical College, Shantou, 515051, Guangdong, China.
- Research Center of Translational Medicine, Second Affiliated Hospital of Shantou University Medical College, Shantou, 515051, Guangdong, China, st120.cn.
ORCID-Profile: Yinglong Chen, Shijie Tang, Wancong Zhang
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Yang, J., Chen, Y., Jing, H., Liu, C., Chen, X., Chu, J., Chen, L., Tang, S., Yu, F., & Zhang, W. (2026). Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β‐Cell Regeneration, Immune Modulation, and Exosome‐Mediated Glucose Homeostasis. Stem Cells International, 2026(1). https://doi.org/10.1155/sci/2759804
Vancouver
Yang J, Chen Y, Jing H, Liu C, Chen X, Chu J, et al. Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β‐Cell Regeneration, Immune Modulation, and Exosome‐Mediated Glucose Homeostasis. Stem Cells International. 2026;2026(1). doi:10.1155/sci/2759804
BibTeX
@article{Yang2026,
author = {Yang, Jia and Chen, Yinglong and Jing, Huanmei and Liu, Chang and Chen, Xiaoling and Chu, Jiaju and Chen, Liyun and Tang, Shijie and Yu, Fei and Zhang, Wancong},
title = {Mesenchymal Stem Cell Therapy for Type 2 Diabetes: Synergistic β‐Cell Regeneration, Immune Modulation, and Exosome‐Mediated Glucose Homeostasis},
journal = {Stem Cells International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/sci/2759804}
}
EUVIMED